Evidence map›Paper›PMID 42453186›Full record

ReviewNeuro-oncology practice2026

Primary central nervous system lymphoma-current standards and recent developments.

Matthijs Van Der Meulen, Joost S P Vermaat, Norbert Galldiks, Samar Issa, Jeroen De Bresser, Jeanette K Doorduijn, Jacoline E C Bromberg

Abstract readReview
In one paragraph

Review in Neuro-oncology practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Matthijs Van Der MeulenDepartment of Neurology, Leiden University Medical Center, Leiden, the Netherlands.ORCID https://orcid.org/0000-0002-2251-9933
Joost S P VermaatDepartment of Hematology, Leiden University Medical Center, Leiden, the Netherlands.
Norbert GalldiksDepartment of Neurology, University Hospital Cologne, Cologne, Germany.ORCID https://orcid.org/0000-0002-2485-1796
Samar IssaDepartment of Hematology, Middlemore Hospital, Auckland, New Zealand.ORCID https://orcid.org/0009-0008-2534-3428
Jeroen De BresserDepartment of Radiology, Leiden University Medical Center, Leiden, the Netherlands.ORCID https://orcid.org/0000-0003-0759-8407
Jeanette K DoorduijnDepartment of hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID https://orcid.org/0000-0002-1014-0918
Jacoline E C BrombergDepartment of neurology, Erasmus MC Cancer Institute, Brain Tumor Center, University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID https://orcid.org/0000-0002-3830-7142

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary central nervous system lymphoma (PCNSL) is a rare aggressive B-cell non-Hodgkin lymphoma confined to the central nervous system, without systemic involvement. The incidence has increased over the past 3 decades. The prognosis has improved in patients up to 70 years old, and this type of lymphoma can be potentially cured. The gold standard of diagnosing PCNSL is histological, usually on a brain biopsy specimen via a neurosurgical procedure. Recent developments in both imaging and laboratory analyses of the cerebrospinal fluid, can be helpful in narrowing the differential diagnosis, diagnosing PCNSL itself, and in follow-up after treatment. This narrative review gives an overview of the epidemiology, diagnosis, and treatment of PCNSL, with an emphasis on recent developments in diagnostic techniques and treatment.

Indexed as

[18F]FDG-PETImaging|liquid biopsyMRItreatment

Identifiers

PMID42453186
PMCPMC13365151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.